vimarsana.com
Home
Live Updates
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024 : comparemela.com
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024
PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and...
Related Keywords
United States ,
Texas ,
London ,
City Of ,
United Kingdom ,
Manchester ,
Alabama ,
Claremont ,
Surrey ,
American ,
Frank Sciurba ,
Mark Dransfield ,
Donald Mahler ,
Antonio Anzueto ,
Ravi Kalhan ,
Verona Pharma ,
Nathan Marchetti ,
Dave Singh ,
Leslie Humbel ,
Northwestern University ,
University Of Pittsburgh Medical Center ,
Lewis Katz School Of Medicine ,
American Thoracic Society International Conference ,
Temple University ,
Nasdaq ,
Bridge Communications ,
University Of Pittsburgh School Medicine ,
Globenewswire Inc ,
International Us Media Enquiries ,
University Of Manchester ,
Drug Administration ,
Action Date ,
Thoracic Society International Conference ,
Late Breaking Mini Symposium ,
Critical Care ,
Associate Professor ,
Pittsburgh School ,
Breaking Mini Symposium ,
Ensifentrine Reduces Exacerbation Frequency ,
Delays Progression ,
Pittsburgh Medical ,
Late Breaking Abstracts ,
Improved Lung Function ,
Reduced Exacerbations ,
Symptomatic Subjects ,
Alabama Birmingham ,
Selective Inhibitor ,
Severe Exacerbation Rate ,
Subjects With ,
Baseline Blood ,
Ensifentrine Added ,
Symptomatic Subjects With Moderate To Severe ,
Thoracic Medicine ,
Katz School ,
Life Reported With Ensifentrine ,
Pooled Analysis ,
Respiratory Pharmacology ,
Subjects With Symptomatic Moderate To Severe ,
Improved Dyspnea ,
Subjects With Symptomatic ,
Regional Hospital ,
Reduced Dyspnea ,
Improved Quality ,
Pulmonary Critical Care ,
Kingdom Tel ,
Senior Director ,
Investor Relations ,
Annual Report ,
Quarterly Reports ,
comparemela.com © 2020. All Rights Reserved.